Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 2

A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control

NCT06579287 · View on ClinicalTrials.gov ↗

Study Summary

The objective of this study is to explore the safety and efficacy of SHJ002 Sterile Ophthalmic Solution relative to atropine in myopia control SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.

Conditions Studied

Interventions

  • DRUG Atropine
  • DRUG SHJ002

Study Locations (9)

Other

  • Changhua Christian Hospital — Chang-hua
  • Kaohsiung Veterans General Hospital — Kaohsiung City
  • Chang Cung Memorial Hospital-Tucheng — New Taipei City
  • MacKay Memorial Hospital-Tamsui — New Taipei City
  • Chung Shan Medical University Hospital — Taichung
  • Cathay General Hospital — Taipei
  • Taipei Veterans General Hospital — Taipei
  • Tri-Service General Hospital — Taipei

Ohio

  • Pacific Center for Advanced Vision Care Tanasbourne Vision Center — Hillsboro

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2025-01-22
Est. Completion 2026-12
Phase Phase 2

Sponsor

Sunhawk Vision Biotech

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06579287

The ClinicalTrials.gov registry entry for NCT06579287 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunhawk Vision Biotech, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Myopia, Progressive appearing as the primary indexed condition, and to 2 interventions — of which Atropine is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06579287 reports 9 study locations spanning 2 distinct geographic areas — top geographies include Other, Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06579287 about?

NCT06579287 is a clinical study titled "A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control". The objective of this study is to explore the safety and efficacy of SHJ002 Sterile Ophthalmic Solution relative to atropine in myopia control SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.

What is the current status of trial NCT06579287?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2025-01-22. Estimated completion is 2026-12.

What conditions does trial NCT06579287 study?

This clinical trial studies the following conditions: Myopia, Progressive. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06579287?

The interventions under investigation include: Atropine (DRUG), SHJ002 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06579287?

This trial is sponsored by Sunhawk Vision Biotech, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06579287 being conducted?

This trial has 9 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial